Domainex Ltd was established in 2001 and operates from sites in London and Cambridge UK. In May 2007 Domainex merged with NCE Discovery at Cambridge to form a new integrated Company with capabilities in biology and chemistry. Our biology division offers technologies designed to clone and express challenging genes, or functional domains of the gene products, to deliver high-quality recombinant protein. Our chemistry division, NCE Discovery, offers experienced computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins. Our drug development division seeks to exploit these technologies and expertise within internal projects. Our internal programmes are exclusively focussed on nucleotide binding domains (NBDs) found in several important therapeutic targets.
ASINEX offers wide-ranging opportunities for collaboration in all relevant research fields: custom library synthesis, hit-to-lead projects, lead optimization and exclusive library synthesis. ASINEX chemistry know-how has truly evolved from every-day combinatorial approaches. We apply our medicinal chemistry expertise and proprietary techniques in organic synthesis to service-based chemistry projects. ASINEX has developed a trustworthy reputation as a provider of outsourcing since the completion of our first project more than 7 years ago. A special advantage of ASINEX is an impressive in-house library of building blocks which are particularly useful for optimizing various parameters of lead compounds or for generating diversity orientated or target-specific libraries. Along with "easy" chemical reactions (i.e. amide coupling, sulfonamide formation reductive amination) which are commonly used for the preparation of large compound libraries, ASINEX chemists are willing to explore a variety of modern synthetic techniques (e.g. boronic acid coupling, phenol and sulphonamide arylation, epoxide opening, C-C coupling reactions, multicomponent reactions, nucleophilic aromatic substitution, cycloaddition, cyclisations and heterocycle formations protection-deprotection sequence etc.) We are able to perform both solution phase and solid phase synthetic methodologies. ASINEX has a trustworthy reputation as a provider of chemistry services. Please review our references.
http://www.noabbiodiscoveries.com
NoAb BioDiscoveries provides a wide range of innovative drug discovery services and tools designed to accelerate the drug development process. Our focus is on lead selection and optimization. We provide pharmaceutical developers In Vivo PK (Pharmacokinetics) studies, In Vitro ADME (Absorption, Distribution, Metabolism, and Excretion) assays, Bioanalytical services, and Gene Expression profiling of drug effects. Our state-of-the-art 12,600 sq. ft. research facility is located in the heart of one of North America's key biotech hubs, with convenient access from centers around the world. Our team of experienced scientists can assist in designing the best strategy and protocols to suit any drug discovery need.
Biotage AB, formerly Pyrosequencing AB, is a Sweden-based company active within the biotechnology sector. The Company provides solutions in the areas of medicinal and analytical chemistry, process development and genetic analysis. Its business activities are divided into two segments: Discovery Chemistry and Biosystems. The Discovery Chemistry area supplies systems and consumables within pharmaceutical chemistry, including such areas as synthesis, work-up, purification and evaporation. Its solutions are marketed under the brand names of Initiator, Advancer, ISOLUTE, EVOLUTE, Isolera, FlashMaster and others. The Biosystems area offers systems for genetic analysis, mainly for the use in clinical research. It focuses its operations on two application areas: infectious disease and cancer research. The Biosystems’ activities are based on the Pyrosequencing technology, in which a sample’s deoxyribonucleic acid (DNA) sequences are read in real time with the help of sequencing by synthesis.
BioFocus is a leading drug discovery company working in partnership with major pharmaceutical and biotechnology companies. Additionally it is developing a portfolio of internal drug discovery programmes aimed at providing drug leads for partnering. The company was founded in 1997 and is quoted on the Alternative Investment Market of the London Stock Exchange. BioFocus works with a wide range of global clients has provided services and/or products to 24 out of the top 30 pharmaceutical companies worldwide.
http://www.argentadiscovery.com
Argenta Discovery is a respiratory-focused pharmaceutical R&D company. Argenta is developing a pipeline of novel therapies to treat serious diseases such as chronic obstructive pulmonary disease (COPD), severe steroid-insensitive asthma, allergic asthma and cystic fibrosis (CF) with the aim of delivering both improved symptomatic relief and treating the underlying inflammatory disease process. Argenta intends to progress its programmes through Phase IIa proof of concept clinical trials before partnering.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory